Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Appoints Craig A. Wheeler to Board of Directors
Summary
On April 17, 2025, Apellis Pharmaceuticals, Inc. announced the election of Craig A. Wheeler to its Board of Directors as a Class III director. Wheeler, who has extensive experience in the biotechnology sector, will serve on the Audit Committee and will be compensated in line with other non-employee directors. He was also granted stock options and restricted stock units under the Company's 2017 Stock Incentive Plan.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement